I-CARE
15.2.2024 14:31:33 CET | Business Wire | Press release
I-care, world leader in machine health, today presented the latest innovation in its Wi-care product range, the Wi-care 130 G23. This is the very first high-precision vibration sensor manufactured entirely in Belgium, capable of predicting more and more industrial breakdowns at an ever earlier stage. It is 100% autonomous, and therefore wireless, with a data flow that is 3 times more powerful and a battery life of 5 years. Thanks to this new technological innovation, I-care is strengthening AI-powered industrial maintenance 4.0. and enabling industries around the world to be more productive, safer and more sustainable.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240215735570/en/
Wi-care 130 G23 (Photo: I-care)
The Wi-care 130 G23, the very first sensor to be manufactured entirely in Belgium, is a revolution in the predictive maintenance business. It is an innovative tool capable of carrying out 3 types of measurement on machines simultaneously: vibration analysis, shock identification and temperature monitoring. It incorporates the state-of-the-art technologies, in particular piezoelectric sensors, and works on all types of industrial machine.
The Wi-care 130 G23 is 100% autonomous, and therefore wireless. It has a battery that will last for more than 5 years of uninterrupted use, even when taking high-precision measurements that consume a lot of energy. The sensor is ATEX certified, with a data stream 3 times more powerful, offering high resolution and high frequency.
Like all products in the Wi-care range, this new sensor from I-care is fully integrated into the WaaS (Wi-care as a Service) ecosystem, an all-inclusive machine maintenance solution covering everything from hardware to support services via the iSee platform, including analysis and reporting. .
I-care is an expert in analysing machine vibrations to predict industrial failures months or even years before they occur. The Wi-care 130 G23 enables errors to be detected at an early stage, so that more and more industrial failures can be predicted earlier and earlier. In this way, I-care is delivering on its mission to "change the way the world works" by making industries around the world more efficient, safer and more environmentally friendly.
"With the Wi-care 130 G23, not only the design but also, and above all, the performance of Wi-care has been enormously improved. It's a real revolution, and 100% Belgian," says Fabrice Brion, CEO of I-care. "Above all, it's about enabling the industrial manufacturing companies to work better. At I-care, this is our way of contributing to a more efficient and sustainable economy.”
About I-care
The I-care Group is a world leader in machine health. Our mission is to change the way the world works. Our AI and data-driven solutions predict industrial failures months or even years before they occur. Thanks to I-care, machines around the world are safer, more productive and more sustainable. Founded in 2004 in Mons, Belgium, we employ over 800 people, with 36 offices in 16 countries (Asia-Pacific, EMEA and the US) and customers in over 55 countries.
Pictures Wi-care 130 G23
Please find the pictures of the Wi-care 130 G23 here.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240215735570/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom